View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. Haselmeier
3 May 2018

Haselmeier and Common Sensing Enter Connected Injectable Medicine Collaboration

Haselmeier and smart injector monitoring and support solutions company Common Sensing have announced a partnership agreement to develop smart connected monitoring and support solutions for users of injectable medicines.

Worldwide, more than 16 billion injections of medicine are administered every year. Smart connected monitoring solutions for users of injectables are aimed to helping them to properly administer those medicines to improve efficacy and quality of therapies.

Haselmeier’s subcutaneous drug delivery injection systems for self-administration will be combined with Common Sensing’s Gocap injector monitoring technology, creating a first-of-its-kind, next generation, smart disposable injector pen platform, to be available in 2019.

This platform will be sold by Haselmeier and is expected to drive significant interest from new and existing Haselmeier injector customers. The combined injector pen-Gocap platform will record the time and amount of every injector dose, along with other information like storage temperature.

Haselmeier’s senior advisor and board member Paul Jansen said:  “Haselmeier is excited about the collaboration with Common Sensing. Both companies have recognised how complementary their technologies were and how much this partnership will provide value for both companies and patients. The joint relationship we have built will enable Haselmeier and Common Sensing to rapidly bring a unique connected pen solution on the market.”

Gocap information may be made available for users, caretakers, clinicians, healthcare systems, researchers, and pharmaceutical companies. This information is a critical element of any connected health solution for people using injectable medicine. Gocap dose monitoring has been clinically validated for use with insulin pens in studies at the world-renowned Joslin Diabetes Center, in Boston, Massachusetts, and The University of Massachusetts Memorial Medical Center.

Common Sensing chief operating officer Kevin Schmid said: “This partnership is a fantastic, market shaping opportunity to merge the leading edge, Haselmeier D-Flex injector with our Gocap connected health technology in a scalable, commercial platform.”

Haselmeier has a history of developing innovative mechanical drug delivery solutions, including Haselmeier’s most recent and innovative D-Flex injector, which may be used with both fixed-dose or selectable dose regimen. The addition of a custom-designed Gocap injector monitor to the Haselmeier product portfolio will allow pharmaceutical customers to quickly launch connected injectable medicines into the market with existing and new Haselmeier pens.

Haselmeier chief strategy officer Frédéric Gabriel said: “There is a high need to provide patients the means to better monitor the efficacy of their therapy and the injection experience is a crucial moment in a patient’s therapy. The collaboration of Haselmeier with Common Sensing is a smart and fast way to achieve our objective in improving patients’ lives.”

Type 2 diabetes is a global health problem. According to expert estimates, the number of patients worldwide will increase by 48% by 2045.
The D-Flex injection pen can do more than previous pens. D-Flex can be configured for several fixed-dose values and is thus a variable fixed-dose pen.
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology